Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Mar;29(3):259-64.
doi: 10.1007/s10815-011-9708-4. Epub 2012 Jan 10.

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

Ensieh Shahrokh Tehraninejad  1 , Maryam Hafezi, Arezoo Arabipoor, Elham Aziminekoo, Mohammad Chehrazi, Akram Bahmanabadi
Affiliations
Randomized Controlled Trial

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

Ensieh Shahrokh Tehraninejad et al. J Assist Reprod Genet. 2012 Mar.

Abstract

Purpose: To compare the efficacy of cabergoline (Cb2) and intravenous human albumin (HA) in the prevention of ovarian hyperstimulation syndrome.

Methods: In this randomized controlled trial study, 138 women who were at high risk for developing OHSS were randomly allocated into two groups. In Group one, 20 gr of HA 20% was infused over 1 h. Group two received 0.5 mg per day of Cb2 orally for 7 days, starting on oocyte pickup day. All patients were visited seven and 14 days after oocyte retrieval to determine early clinical or ultrasound evidence of OHSS.

Results: Moderate OHSS was observed in 33 versus 14 cases in the HA and Cb2 groups, respectively, which was significantly different. The number of severe OHSS cases in the HA group was significantly higher than in the Cb2 group (P < 0.001).

Conclusions: Prophylactic oral low dose cabergoline was more effective and less costly than intravenous human albumin in the prevention of OHSS in high-risk patients.

Trial registration: ClinicalTrials.gov NCT01009567.

PubMed Disclaimer

References

    1. Mathur R, Kailasam CH, Jenkins J. Review of the evidence base of strategies to prevent ovarian hyper stimulation syndrome. Hum. Fertil. 2007;10(2):75–85. doi: 10.1080/14647270601111239. - DOI - PubMed
    1. Shoham Z, Weissman A, Barasch A, Borenstein R, Schachter M, Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril. 1994;62:137–142. - PubMed
    1. Isik AZ, Gokmen O, Zeyneloglu HB, Kara S, Keles G, Gulekli B. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in-vitro fertilization patients: a prospective randomized and controlled study. Eur J Obstet Gynecol Reprod Biol. 1996;70:179–83. doi: 10.1016/S0301-2115(95)02603-7. - DOI - PubMed
    1. Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme:a prospective randomized placebo controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001;96:187–92. doi: 10.1016/S0301-2115(00)00452-8. - DOI - PubMed
    1. Ben-Chetrit A, Eldar-Geva Y, Gal M, Huerta M, Mimon T, Algur N, Diamant YZ, Margalioth EJ. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum. Reprod. 2001;16:1880–4. doi: 10.1093/humrep/16.9.1880. - DOI - PubMed

Publication types

MeSH terms

Associated data